Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
- 15 November 2012
- journal article
- practice guideline
- Published by Wiley in British Journal of Haematology
- Vol. 160 (2), 153-170
- https://doi.org/10.1111/bjh.12091
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studiesJournal of Thrombosis and Haemostasis, 2011
- Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIIIJournal of Thrombosis and Haemostasis, 2011
- The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experienceJournal of Thrombosis and Haemostasis, 2011
- Concentrate‐related inhibitor risk: is a difference always real?Journal of Thrombosis and Haemostasis, 2011
- The value of early treatment in patients with haemophilia and inhibitorsHaemophilia, 2010
- Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoringJournal of Thrombosis and Haemostasis, 2010
- Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitorsHaemophilia, 2009
- Inhibitors of Factor VIII in Black Patients with HemophiliaNew England Journal of Medicine, 2009
- Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitorsHaemophilia, 2007
- Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia AHaemophilia, 2007